西罗莫司片医保给报销吗？

Sirolimus is a new type of immunosuppressant developed by the American Wyeth Company. The drug was approved by the FDA as early as September 1999 and officially launched in the United States. It was later approved for sale in China in 2002. Sirolimus tablets are a Western-style medicine that contains sirolimus as the main ingredient and is formulated through multiple processes. The medicine is used to treat patients who have received kidney transplants and to prevent organ rejection. Will sirolimus tablets be reimbursed by medical insurance?

Sirolimus tablets (Repamin) have been included in the National Medical Insurance List (Category B) and are classified as medical insurance drugs. Category: anti-tumor drugs and immunomodulators > immunosuppressants > immunosuppressants > selective immunosuppressants. Class B medical insurance drugs can be reimbursed according to local medical insurance reimbursement policies.

Rapamin () can inhibit the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukins IL-2, IL-4 and IL-15). It also inhibits the production of antibodies. In cells, sirolimus binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate the FKBP-12 immunosuppressive complex. This complex binds to the mammalian sirolimus BA molecule (mTOR, a key regulatory kinase) and inhibits its activity, thereby inhibiting the progression from G1 to S phase in the cell cycle. In the case of sirolimus tablets, it is recommended that sirolimus be used in combination with cyclosporine and corticosteroids in new kidney transplant recipients. A loading dose of sirolimus should be taken for the first time, which is 3 times the maintenance dose. The recommended loading dose for kidney transplant patients is 6mg and the maintenance dose is 2mg/day, that is, 2 tablets per day.

Recommended related hot articles: /newsDetail/83751.html